• World News
  • Investing
  • Economy
  • Politics
  • Editor’s Pick
Target Line News
Investing

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

by May 15, 2025
by May 15, 2025

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.

HIGHLIGHTS

  • Key milestone achieved, with 15 confirmed responses recorded in the ongoing Phase 1b/2a ACCENT trial
  • Sufficient confirmed responses have now been recorded to demonstrate that narmafotinib combined with chemotherapy is superior to chemotherapy alone.
  • The ACCENT trial is evaluating narmafotinib in combination with the chemotherapies gemcitabine and Abraxane® in patients with advanced pancreatic cancer
  • Narmafotinib is a highly potent and selective FAK inhibitor discovered at the Melbourne-based Cooperative Research Centre for Cancer Therapeutics.
  • Phase 2a ACCENT trial is fully recruited with top-line data expected in mid Q3 2025

A confirmed partial response is a formal designation of response where tumour shrinkage >30% is recorded and sustained for two (2) or more months and where no new cancerous lesions have been detected. As pancreatic cancer is highly aggressive it is extremely rare for patients to achieve a complete response (CR).

The ACCENT trial is an open-label study meaning that all patients on the study receive narmafotinib in combination with the standard-of-care therapy. The data obtained in this trial is compared to historical data for the combination of gemcitabine and Abraxane in pancreatic cancer, and specifically data from the MPACT study, upon which we have closely modelled our trial1.

At the outset of the study a statistical analysis was performed which identified that a patient cohort of 50 patients would be sufficient to allow the efficacy of our combination to be ascertained with reasonable confidence if 15 or more responders (confirmed PR or CR) were recorded. A total of 55 advanced pancreatic patients have enrolled in the study since January 2024, with 21 patients still on study at this time.

As noted in our recent press release2, the drug continues to be well tolerated by patients with the rate and type of adverse events for the narmafotinib combination being similar to that reported for chemotherapy alone.

Amplia CEO and MD Dr Chris Burns commented: “We are extremely excited to have now recorded 15 confirmed partial responses in the ACCENT trial, demonstrating the benefit of adding narmafotinib to standard-of-care chemotherapy. With over 20 patients still on study we are hopeful that further PR’s will be observed”

Click here for the full ASX Release

This post appeared first on investingnews.com

0 comment
0
FacebookTwitterPinterestEmail

previous post
Eric Nuttall: Oil vs. Natural Gas Stocks, Plus 2025 Prices, Supply and Demand
next post
Multiple Uranium Anomalies Identified at Key NT Projects

You may also like

Multiple Uranium Anomalies Identified at Key NT Projects

May 15, 2025

EL2780 Award – New Targets from Airborne MT

May 15, 2025

Eric Nuttall: Oil vs. Natural Gas Stocks, Plus...

May 15, 2025

SAGA Metals Appoints Vernon Shein, Former Exploration Manager...

May 15, 2025

Q1 2025 Management’s Discussion and Analysis

May 14, 2025

Director led financing and change of Chairman

May 14, 2025

JZR Gold Inc. Announces Completion of Testing of...

May 14, 2025

Is Now a Good Time to Buy Bitcoin?

May 14, 2025

Gold Price Drops Over US$100 as US and...

May 14, 2025

Pan American to Buy MAG Silver in US$2.1...

May 13, 2025







    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: targetlinenews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 targetlinenews.com | All Rights Reserved

    Target Line News
    • World News
    • Investing
    • Economy
    • Politics
    • Editor’s Pick